TMS Therapy Success Rates: What the Clinical Data Shows for Each Condition

The average TMS therapy success rate for treatment-resistant depression typically ranges between 50% and 70% for clinical response, with approximately one-third of patients achieving full remission. At Paxina Health, we provide these statistics to ensure every patient maintains informed, realistic expectations before beginning their neuromodulation journey. Clinical data confirms that Transcranial Magnetic Stimulation (TMS) is a highly effective, non-invasive intervention for those who have not found relief through traditional pharmacology. This guide analyzes the most current clinical evidence across every condition treated by TMS, defining success through the rigorous lens of response and remission metrics.

How Clinicians Define TMS Success: Response Rates vs. Remission Rates

Clinicians define the TMS therapy success rate using two primary metrics: response and remission, both of which are measured through validated symptom scales. A "response" is achieved when a patient’s symptom severity decreases by at least 50% from their baseline score. This is typically measured using the Hamilton Depression Rating Scale (HDRS-17) or the Patient Health Questionnaire-9 (PHQ-9). While a response indicates a significant and life-altering improvement in quality of life, the patient may still experience some residual symptoms of their condition.

Remission represents the highest tier of clinical success, occurring when symptoms diminish to the point that the patient no longer meets the diagnostic criteria for the disorder. On the HDRS-17, remission is generally defined as a score of 7 or lower, while a PHQ-9 score of 4 or less indicates remission. Understanding these tiers is essential for patients because while most people respond to treatment, approximately one-third achieve a state of complete clinical recovery.

TMS success is categorized into response (50% improvement) and remission (full clinical recovery). These outcomes are objectively tracked by clinicians using standardized tools like the HDRS-17 and PHQ-9 to ensure data-driven care.

TMS for Depression Efficacy: What Major Clinical Studies Report

Current clinical data indicates that TMS for depression efficacy is remarkably high for patients with treatment-resistant depression (TRD), showing response rates of 50-70% across large-scale registries. For individuals who have failed two or more antidepressant medications, TMS remission rates consistently hover between 30% and 37% in controlled trials. Real-world data, such as that from the NeuroStar Clinical Outcomes Registry, suggests even higher success, with up to 83% of patients showing a clinical response and 62% achieving full remission.

The disparity between clinical trial data and real-world results often stems from the flexibility of clinical practice. While trials follow rigid, unchangeable protocols, providers like Paxina Health can personalize treatment parameters to the patient's specific physiological needs. A 2023 meta-analysis published in BMC Psychiatry confirmed these findings, stating that patients receiving active repetitive TMS (rTMS) were nearly three times more likely to achieve remission than those receiving a placebo (sham) treatment.

The Impact of the Stanford Accelerated Protocol (SAINT)

The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol has significantly elevated the ceiling for TMS remission rates. By delivering 50 sessions of intermittent theta-burst stimulation (iTBS) over just five days—guided by functional MRI imaging—SAINT achieved a 79% remission rate in its pivotal trial. This represents the most rapid and robust success rate currently documented for any non-invasive depression treatment.

TMS for depression efficacy ranges from 50% to 90% depending on the specific protocol used. The SAINT protocol currently offers the highest documented remission rate at 79%, providing a rapid alternative to standard six-week courses.

TMS Success Rates for Obsessive-Compulsive Disorder (OCD)

Deep TMS (dTMS) provides a 38% response rate for treatment-resistant OCD in controlled clinical environments, offering a vital alternative for patients who do not respond to SSRIs. The FDA cleared dTMS for OCD in 2018 following a multi-center study led by Carmi et al., which demonstrated that patients receiving active stimulation experienced a significant reduction in their Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores. In this study, clinical response was defined as a 30% or greater reduction in obsessive-compulsive symptoms.

Real-world applications of TMS for OCD often exceed these trial numbers. A post-marketing study of 219 patients found that 72.6% achieved a clinical response after completing the full protocol. It is important to note that TMS is typically used as an adjunctive treatment for OCD, meaning it works most effectively when combined with ongoing medication and Exposure and Response Prevention (ERP) therapy.

Deep TMS is a proven intervention for OCD with a 38% response rate in trials and over 70% in real-world settings. It is most effective when integrated into a comprehensive plan including therapy and medication.

Off-Label TMS Applications: Anxiety, PTSD, and Emerging Research

While depression and OCD are the primary conditions treated by TMS with FDA clearance, clinical research shows a large treatment effect for anxiety and PTSD. Meta-analyses of TMS for Generalized Anxiety Disorder (GAD) have documented significant anxiolytic effects, with symptoms on the GAD-7 scale often improving in tandem with depressive symptoms. Although these applications are technically "off-label," they are supported by a growing body of peer-reviewed evidence.

For Post-Traumatic Stress Disorder (PTSD), a VA Clinical TMS Program study reported response rates between 63% and 78%. The most effective protocols for PTSD typically involve high-frequency stimulation over the right dorsolateral prefrontal cortex. As more data emerges, these off-label uses are becoming standard options for patients who have exhausted traditional trauma-informed therapies and pharmacological interventions.

TMS shows high efficacy for anxiety and PTSD, with PTSD response rates reaching up to 78% in specialized clinical programs. These off-label uses provide a data-backed alternative for complex, treatment-resistant trauma and anxiety disorders.

How Age Affects TMS Outcomes: Adolescents and Older Adults

The TMS therapy success rate remains consistent across the lifespan, with recent FDA clearance extending treatment to adolescents aged 15 and older. In a study of over 1,200 young patients, approximately 70% of adolescents reported a meaningful clinical response, while 36% achieved full remission. These figures mirror the success rates seen in young adults, confirming that the adolescent brain is highly receptive to neuromodulation.

In the older adult population, TMS remains a safe and effective option for late-life depression. Research involving patients aged 60 and above shows response rates between 38% and 57%, which are statistically comparable to younger cohorts. Because TMS lacks the systemic side effects of antidepressant medications—which can be particularly burdensome for seniors—it is often a preferred second-line treatment for older patients.

TMS is effective for both adolescents (70% response) and older adults (up to 57% response). Age is not a limiting factor for efficacy, making TMS a versatile tool for patients from age 15 through late adulthood.

How Long Do the Effects of TMS Last?

The durability of the TMS therapy success rate is high, with approximately 62.5% of patients who achieve remission maintaining their results one year after treatment. Research indicates that the majority of responders sustain their clinical improvements for 6 to 12 months. While TMS is not a permanent "cure," it provides a long-term window of relief that allows many patients to re-engage with their lives, careers, and therapy goals.

For those who notice a gradual return of symptoms, maintenance TMS sessions can be utilized to "boost" the original results. These sessions are typically less frequent than the initial intensive course. Factors that contribute to longer-lasting results include maintaining a healthy sleep architecture, regular physical activity, and continued engagement in psychotherapy.

Over 60% of patients remain in remission one year after completing TMS. Durability is enhanced through maintenance sessions and lifestyle support, providing lasting relief for the majority of treatment responders.